{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:49:40Z","timestamp":1786564180424,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJ4 179807"],"award-info":[{"award-number":["PJ4 179807"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although there are no approved countermeasures available to prevent or treat disease caused by Marburg virus (MARV), potently neutralizing monoclonal antibodies (mAbs) derived from B cells of human survivors have been identified. One such mAb, MR191, has been shown to provide complete protection against MARV in nonhuman primates. We previously demonstrated that prophylactic administration of an adeno-associated virus (AAV) expressing MR191 protected mice from MARV. Here, we modified the AAV-MR191 coding sequence to enhance efficacy and reevaluated protection in a guinea pig model. Remarkably, 4 different variants of AAV-MR191 provided complete protection against MARV, despite administration 90 days prior to challenge. Based on superior expression kinetics, AAV-MR191-io2, was selected for evaluation in a dose-reduction experiment. The highest dose provided 100% protection, while a lower dose provided \u223c88% protection. These data confirm the efficacy of AAV-mediated expression of MR191 and support the further development of this promising MARV countermeasure.<\/jats:p>","DOI":"10.1093\/infdis\/jiad345","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T14:45:40Z","timestamp":1693233940000},"page":"S682-S690","source":"Crossref","is-referenced-by-count":10,"title":["AAV-Vectored Expression of Marburg Virus\u2013Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model"],"prefix":"10.1093","volume":"228","author":[{"given":"Amira D","family":"Rghei","sequence":"first","affiliation":[{"name":"Department of Pathobiology, University of Guelph , Guelph, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Cao","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"He","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn A","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph , Guelph, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zielinska","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph , Guelph, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph , Guelph, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Thompson","sequence":"additional","affiliation":[{"name":"Avamab Pharma, Inc , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-2648","authenticated-orcid":false,"given":"Logan","family":"Banadyga","sequence":"additional","affiliation":[{"name":"Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada , Winnipeg, Manitoba , Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K","family":"Wootton","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph , Guelph, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"2023111521061808700_jiad345-B1","first-page":"450","volume-title":"Filoviridae","author":"Kuhn","year":"2021","edition":"7th ed"},{"key":"2023111521061808700_jiad345-B2","author":"World Health Organization"},{"key":"2023111521061808700_jiad345-B3","author":"World Health Organization"},{"key":"2023111521061808700_jiad345-B4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17460441.2022.2013800","article-title":"The discovery and development of novel treatment strategies for filoviruses","volume":"17","author":"Bradfute","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"2023111521061808700_jiad345-B5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/pathogens11030374","article-title":"Development and structural analysis of antibody therapeutics for filoviruses","volume":"11","author":"Yu","year":"2022","journal-title":"Pathogens"},{"key":"2023111521061808700_jiad345-B6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"key":"2023111521061808700_jiad345-B7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/scitranslmed.aai8711","article-title":"Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody","volume":"9","author":"Mire","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023111521061808700_jiad345-B8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4161\/hv.4.1.4778","article-title":"Antibody gene-based prophylaxis and therapy for biodefence","volume":"4","author":"Hu","year":"2008","journal-title":"Hum Vaccin"},{"key":"2023111521061808700_jiad345-B9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.coi.2015.06.014","article-title":"Engineering humoral immunity as prophylaxis or therapy","volume":"35","author":"Deal","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"2023111521061808700_jiad345-B10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2023111521061808700_jiad345-B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00361-2","article-title":"Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep","author":"Rghei","journal-title":"Gene Ther"},{"key":"2023111521061808700_jiad345-B12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.omtm.2022.08.003","article-title":"AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge","volume":"26","author":"van Lieshout","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2023111521061808700_jiad345-B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omtm.2018.04.005","article-title":"A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice","volume":"9","author":"van Lieshout","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2023111521061808700_jiad345-B14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci Transl Med"},{"key":"2023111521061808700_jiad345-B15","doi-asserted-by":"crossref","DOI":"10.3791\/62727-v","article-title":"Production of adeno-associated virus vectors in cell stacks for preclinical studies in large animal models","author":"Rghei","year":"2021","journal-title":"J Vis Exp"},{"key":"2023111521061808700_jiad345-B16","first-page":"2223","article-title":"Recent advancements in AAV-vectored immunoprophylaxis in the nonhuman primate model","volume":"11","author":"Campbell","year":"2023","journal-title":"Biomed"},{"key":"2023111521061808700_jiad345-B17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"2023111521061808700_jiad345-B18","doi-asserted-by":"crossref","first-page":"113324","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2023111521061808700_jiad345-B19","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fmed.2021.809118","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2022","journal-title":"Front Med"},{"key":"2023111521061808700_jiad345-B20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/tropicalmed5040169","article-title":"AAV vectored immunoprophylaxis for filovirus infections","volume":"5","author":"Rghei","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"2023111521061808700_jiad345-B21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fcimb.2020.00176","article-title":"Promise and progress of an HIV-1 cure by adeno-associated virus vector delivery of anti-HIV-1 biologics","volume":"10","author":"Gardner","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2023111521061808700_jiad345-B22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat Med"},{"key":"2023111521061808700_jiad345-B23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/infdis\/jix644","article-title":"Intramuscular adeno-associated virus\u2013mediated expression of monoclonal antibodies provides 100% protection against Ebola virus infection in mice","volume":"217","author":"van Lieshout","year":"2018","journal-title":"J Infect Dis"},{"key":"2023111521061808700_jiad345-B24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17460441.2018.1527827","article-title":"Small animal models of filovirus disease: recent advances and future directions","volume":"13","author":"Cross","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"2023111521061808700_jiad345-B25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J Innate Immun"},{"key":"2023111521061808700_jiad345-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 Signaling mediates adaptive immunity following systemic AAV gene therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad345\/51277580\/jiad345.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S682\/53451846\/jiad345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S682\/53451846\/jiad345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:14:04Z","timestamp":1700082844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_7\/S682\/7252744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":26,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2023,8,28]]},"published-print":{"date-parts":[[2023,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad345","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,8,28]]}}}